Pérez SU, Pérez A

Language: Spanish
References: 22
Page: 176-176
PDF size: 365.20 Kb.

ABSTRACT

Anemia frequently accompanies chronic diseases although its pathogenesis and etiology remains obscure. It occurs in adults and children, is usually moderate but it deserves treatment to improve the general condition even if it does not affect the primary illness. Among possible pathogenic mechanisms are included: life shortening of erythrocytes, lesser response to normal readjustment mechanisms, maturation impairment of red-cell precursors, diminished utilization of reticulo-endothelial iron or influence of inflammatory cytokines. Erithropoietin is a growth factor of red-cells and in its recombinant form is used in clinical medicine. Various researches have carried-out double-blind studies on rheumatoid arthritis patients with encouraging results. Hemoglobin can be raised to normal although pain and stiffness keep unchanged but patients feel better. It is then an advisable coadjuvant to antiinflammatory and analgesics therapy.

REFERENCES

1. Ruiz-Argüelles GJ. Fundamentos de hematología. 2a. ed. México: Panamericana, 1998.

2. Means R. Clinical application of recombinant erytropoietin in the anemia of chronic disease. Hematology/Oncology Clinics of North America 1994; 8: 933-44.

3. Dordal MS, Wang FF, Goldwasser E. The role of carbohydrate in erytropoietin action. Endocrinology 1985; 116: 2293-99.

4. Zanjani ED, Poster J, Burlington H et al. Liver as the primary site of erytropoietin production in the fetus. J Lab Clin Med 1977; 89: 640.

5. Koury ST, Bondurant MC, Koury MJ. Localization of erytropoietin synthesizing cells in murine kidneys by in situ hybridization. Blood 1988; 71: 524.

6. Polisson R. MKSAP en Reumatología. 2a. Ed. American College of Rheumatology, 1999.

7. Alarcón GS. Epidemiología de las enfermedades reumáticas en América Latina. Bol Of Sanit Panam 1986; 4: 101.

8. Cartwigth GE, Wintrobe MM. The anemia of infection. Adv Intern Med 1952; 5: 165.

9. Cash JM, Sears DA. The spectrum of diseases associated with the anemia of chronic diseases: A study of 90 cases. Am J Med 1990; 87: 638.

10. Baer AN, Dessypris EN, Krantz SB. The pathogenesis of anemia in rheumatoid arthritis. A clinical and laboratory analysis. Semin Arthritis Rheum 1990; 14: 209.

11. Eschbach JW, Egrie JC, Downing M et al. Correction of de anemia on end stage renal disease with recombinant human erytropoietin: results of a combined fase I and II clinical trial. N Engl J Med 1987; 316: 73-78.

12. Eschbach JW, Kelly MR, Haley NR et al. Treatment of de anemia of progressive renal failure with recombinant human erytropoietin. N Engl J Med 1989; 321: 158-62.

13. Abels RJ, Larholt KM, Krantz KD et al. Recombinant human erytropoietin for the treatment of the anemia of cancer. Murphy MJ Ed. Blood cell Growth Factors: Their present and future use in hematology. Dayton, Ohio; Alpha Med Press 1991: 121-141.

14. Goodnough LT, Marcus RE. The erytropoietic response to erytropoietin in patients with rheumatoid arthritis. J Lab Clin Med 1997; 130: 381-86.

15. Matsui H, Shirashi N, Ysuda T et al. The effects of recombinant human erytropoietin on autologus blood donation in rheumatoid arthritis patients with anemia. Clin Exp Rheumatol 1999; 17: 69-74.

16. Goodman and Gilman’s. The Pharmacological Basis of Therapeutics. 8a. Ed. USA: Pergamon Press, 1990.

17. Meabs RT, Olsen NJ, Krantz SB et al. Treatment of the anemia of rheumatoid arthritis with recombinant human erytropoietin: Clinical and in vitro studies. Arthritis Rheum 1989; 32: 638-42.

18. Pincus T, Olsen NJ, Russell J et al. Multicenter study of recombinant human erytropoietin in correction of anemia in rheumatoid arthritis. Am J Med 1990; 89: 161-68.

19. Gudbjörnsson B, Hällgren R, Wide L. Response of anemia rheumatoid arthritis to treatment with subcutaneous recombinant human erytropoietin. Ann Rheum Dis 1992; 51: 747-52.

20. Petterson T, Rosenlöf K, Friman C et al. Successful treatment of the anemia of rheumatoid arthritis with subcutaneously administered recombinant human erytropoietin. Scand J Rheumtol 1993; 22: 188-93.

21. Murphy EA, Bell AL, Wojtulewsky J et al. Study of erytropoietin in treatment of anemia in patients with rheumatoid arthritis. BMJ 1994; 309: 1337-38.

22. Peeters HRM, Jongen-Lavrenic M, Vreugdenhill G et al. Effect of recombinant erytropoietin on anemia and disease activity in patients with rheumatoid arthritis and anemia of chronic disease: a randomized placebo controlled double blind 52 weeks clinical trial. Ann Rheum Dis 1996; 55: 739-44.